Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Gruppo Oncologico Italiano di Ricerca Clinica clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Italy register with Gruppo Oncologico Italiano di Ricerca Clinica as lead sponsor. Synced 17 Nov 2026
12Current trials
7Recruiting now
9Drugs in these trials
1Trial register
At a glance

Gruppo Oncologico Italiano di Ricerca Clinica is the lead sponsor of 12 current clinical trials in our Italy register. 7 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Atezolizumab, Durvalumab and Etoposide. The most-studied condition is Pulmonary Large-cell Neuroendocrine Carcinoma.

ClinicalTrials.gov trials by status

  • Recruiting758%
  • Not yet open325%
  • Active, closed217%

Trials by phase

  • Phase 2758%
  • Observational433%
  • Phase 318%
01

Clinical trials sponsored by Gruppo Oncologico Italiano di Ricerca Clinica

12 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
NCT06418087 · ClinicalTrials.gov ↗ · Pulmonary Large-cell Neuroendocrine Carcinoma
Phase 2 Recruiting 2022-05 Italy
A Prospective Observational Study on of Early-Onset Gastrointestinal Cancer: From Tumor Features to Patient Lifestyle Habits
NCT07479472 · ClinicalTrials.gov ↗ · Early-onset Gastrointestinal Cancer
Observational Recruiting 2026-07 Italy
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
NCT06464068 · ClinicalTrials.gov ↗ · Extrapulmonary Small Cell Carcinoma
Phase 2 Recruiting 2024-01 Italy
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
NCT07363252 · ClinicalTrials.gov ↗ · EGFR-mutated NSCLC
Observational Recruiting 2026-04 Italy
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
NCT04996017 · ClinicalTrials.gov ↗ · Mesotheliomas Pleural
Phase 3 Recruiting 2021-12 Italy
Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC
NCT07356544 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer), HER2
Observational Recruiting 2025-08 Italy
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
NCT06663098 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2 Recruiting 2025-01 Italy
Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
NCT07460245 · ClinicalTrials.gov ↗ · Urothelial Carcinoma
Phase 2 Not yet open 2026-06 Italy
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer
NCT07418931 · ClinicalTrials.gov ↗ · Advanced Squamous Non-Small Cell Lung Cancer
Phase 2 Not yet open 2026-05 Italy
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
NCT07381777 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)
Phase 2 Not yet open 2026-01 Italy
Alectinib in Neo-adjuvant Treatment of Stage III NSCLC
NCT05015010 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Drug: Alectinib
Phase 2 Active, closed 2021-05 Italy
Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer
NCT04612309 · ClinicalTrials.gov ↗ · Colorectal Cancer
Observational Active, closed 2020-10 Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Gruppo Oncologico Italiano di Ricerca Clinica trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Gruppo Oncologico Italiano di Ricerca Clinica trials

13 conditions
Pulmonary Large-cell Neuroendocrine Carcinoma1Urothelial Carcinoma1Early-onset Gastrointestinal Cancer1Extrapulmonary Small Cell Carcinoma1Non Small Cell Lung Cancer1Colorectal Cancer1EGFR-mutated NSCLC1Advanced Squamous Non-Small Cell Lung Cancer1Mesotheliomas Pleural1NSCLC (Advanced Non-small Cell Lung Cancer)1HER21Locally Advanced Rectal Cancer (LARC)1Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Italy127

A trial with sites in more than one country appears in each of those registers.

05

Questions about Gruppo Oncologico Italiano di Ricerca Clinica trials

How many clinical trials does Gruppo Oncologico Italiano di Ricerca Clinica sponsor?

Gruppo Oncologico Italiano di Ricerca Clinica is the lead sponsor of 12 current trials on ClinicalTrials.gov in our Italy register, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Gruppo Oncologico Italiano di Ricerca Clinica trials recruiting?

Yes. 7 of its 12 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Gruppo Oncologico Italiano di Ricerca Clinica testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Atezolizumab (2), Durvalumab (2), Etoposide (2), Alectinib (1) and Carboplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.